Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease

L. S. Schneider, R. Anand, Martin Farlow

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Cholinesterase inhibition appears to be the most promising current option for the symptomatic treatment of the primary cognitive deficits of Alzheimer's disease (AD). We review three prospective, randomized, double- blind, placebo-controlled studies of rivastigmine, an acetylcholinesterase (AChE) subtype-selective, 'pseudo-irreversible' AChE inhibitor, and report results from a pooled analysis of these studies. The overall phase III assessment program enrolled more than 3300 patients at 116 centers in 10 countries. Two studies were based in the USA and one predominantly in Europe, with some US and Canadian centers. The three clinical trials reviewed here included 2126 patients with mild to moderately severe probable AD treated with a flexible dosage range of rivastigmine 6-12 mg/day or 1-4 mg/day, a fixed-dose regimen of 3, 6 or 9 mg/day, or placebo for 26 weeks. In all trials patients showed significant benefit in measures of cognition (Alzheimer's Disease Assessment Scale-cognitive subscale) and clinician's assessment of change (Clinician Interview-Based Impression of Change incorporating caregiver information); in the two pivotal studies patients also showed significant improvement in activities of daily living (as measured prospectively by the domain-specific Progressive Deterioration Scale). The pooled analyses further confirm the efficacy of rivastigmine in the treatment of both the cognitive and functional deficits of mild to moderately severe AD.

Original languageEnglish (US)
JournalInternational Journal of Geriatric Psychopharmacology
Volume1
Issue numberSUPPL. 1
StatePublished - 1998
Externally publishedYes

Fingerprint

Rivastigmine
Alzheimer Disease
Placebos
Cholinesterase Inhibitors
Cholinesterases
Acetylcholinesterase
Activities of Daily Living
Cognition
Caregivers
Clinical Trials
Interviews
Therapeutics

Keywords

  • Acetylcholinesterase inhibitors
  • ADAS-Cog
  • ADENA
  • Alzheimer's disease
  • CIBIC-Plus
  • Progressive Deterioration Scale
  • Rivastigmine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Geriatrics and Gerontology
  • Neuropsychology and Physiological Psychology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. / Schneider, L. S.; Anand, R.; Farlow, Martin.

In: International Journal of Geriatric Psychopharmacology, Vol. 1, No. SUPPL. 1, 1998.

Research output: Contribution to journalArticle

@article{8f5637d426284215aa303919165bab74,
title = "Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease",
abstract = "Cholinesterase inhibition appears to be the most promising current option for the symptomatic treatment of the primary cognitive deficits of Alzheimer's disease (AD). We review three prospective, randomized, double- blind, placebo-controlled studies of rivastigmine, an acetylcholinesterase (AChE) subtype-selective, 'pseudo-irreversible' AChE inhibitor, and report results from a pooled analysis of these studies. The overall phase III assessment program enrolled more than 3300 patients at 116 centers in 10 countries. Two studies were based in the USA and one predominantly in Europe, with some US and Canadian centers. The three clinical trials reviewed here included 2126 patients with mild to moderately severe probable AD treated with a flexible dosage range of rivastigmine 6-12 mg/day or 1-4 mg/day, a fixed-dose regimen of 3, 6 or 9 mg/day, or placebo for 26 weeks. In all trials patients showed significant benefit in measures of cognition (Alzheimer's Disease Assessment Scale-cognitive subscale) and clinician's assessment of change (Clinician Interview-Based Impression of Change incorporating caregiver information); in the two pivotal studies patients also showed significant improvement in activities of daily living (as measured prospectively by the domain-specific Progressive Deterioration Scale). The pooled analyses further confirm the efficacy of rivastigmine in the treatment of both the cognitive and functional deficits of mild to moderately severe AD.",
keywords = "Acetylcholinesterase inhibitors, ADAS-Cog, ADENA, Alzheimer's disease, CIBIC-Plus, Progressive Deterioration Scale, Rivastigmine",
author = "Schneider, {L. S.} and R. Anand and Martin Farlow",
year = "1998",
language = "English (US)",
volume = "1",
journal = "International Journal of Geriatric Psychopharmacology",
issn = "1364-8233",
publisher = "Stockton Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease

AU - Schneider, L. S.

AU - Anand, R.

AU - Farlow, Martin

PY - 1998

Y1 - 1998

N2 - Cholinesterase inhibition appears to be the most promising current option for the symptomatic treatment of the primary cognitive deficits of Alzheimer's disease (AD). We review three prospective, randomized, double- blind, placebo-controlled studies of rivastigmine, an acetylcholinesterase (AChE) subtype-selective, 'pseudo-irreversible' AChE inhibitor, and report results from a pooled analysis of these studies. The overall phase III assessment program enrolled more than 3300 patients at 116 centers in 10 countries. Two studies were based in the USA and one predominantly in Europe, with some US and Canadian centers. The three clinical trials reviewed here included 2126 patients with mild to moderately severe probable AD treated with a flexible dosage range of rivastigmine 6-12 mg/day or 1-4 mg/day, a fixed-dose regimen of 3, 6 or 9 mg/day, or placebo for 26 weeks. In all trials patients showed significant benefit in measures of cognition (Alzheimer's Disease Assessment Scale-cognitive subscale) and clinician's assessment of change (Clinician Interview-Based Impression of Change incorporating caregiver information); in the two pivotal studies patients also showed significant improvement in activities of daily living (as measured prospectively by the domain-specific Progressive Deterioration Scale). The pooled analyses further confirm the efficacy of rivastigmine in the treatment of both the cognitive and functional deficits of mild to moderately severe AD.

AB - Cholinesterase inhibition appears to be the most promising current option for the symptomatic treatment of the primary cognitive deficits of Alzheimer's disease (AD). We review three prospective, randomized, double- blind, placebo-controlled studies of rivastigmine, an acetylcholinesterase (AChE) subtype-selective, 'pseudo-irreversible' AChE inhibitor, and report results from a pooled analysis of these studies. The overall phase III assessment program enrolled more than 3300 patients at 116 centers in 10 countries. Two studies were based in the USA and one predominantly in Europe, with some US and Canadian centers. The three clinical trials reviewed here included 2126 patients with mild to moderately severe probable AD treated with a flexible dosage range of rivastigmine 6-12 mg/day or 1-4 mg/day, a fixed-dose regimen of 3, 6 or 9 mg/day, or placebo for 26 weeks. In all trials patients showed significant benefit in measures of cognition (Alzheimer's Disease Assessment Scale-cognitive subscale) and clinician's assessment of change (Clinician Interview-Based Impression of Change incorporating caregiver information); in the two pivotal studies patients also showed significant improvement in activities of daily living (as measured prospectively by the domain-specific Progressive Deterioration Scale). The pooled analyses further confirm the efficacy of rivastigmine in the treatment of both the cognitive and functional deficits of mild to moderately severe AD.

KW - Acetylcholinesterase inhibitors

KW - ADAS-Cog

KW - ADENA

KW - Alzheimer's disease

KW - CIBIC-Plus

KW - Progressive Deterioration Scale

KW - Rivastigmine

UR - http://www.scopus.com/inward/record.url?scp=0031647045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031647045&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031647045

VL - 1

JO - International Journal of Geriatric Psychopharmacology

JF - International Journal of Geriatric Psychopharmacology

SN - 1364-8233

IS - SUPPL. 1

ER -